Whole-body low-dose computed tomography (WBLDCT) in staging and re-staging of multiple myeloma

Ann Hematol. 2021 May;100(5):1241-1249. doi: 10.1007/s00277-021-04468-1. Epub 2021 Mar 4.

Abstract

The objective of this study is to evaluate the prognostic features of multiple myeloma (MM) using whole-body low-dose computed tomography (WBLDCT). One hundred three patients with biopsy-proven MM who underwent WBLDCT were retrospectively enrolled. The evolution of osteolytic lesions overtime was performed by measuring the maximum axial diameter at the baseline (T0) and the end of follow-up (Te), by using a cut-off value of 10 mm. The location and dimension of up to three lesions were registered. The time-to-fracture (TTF) was recorded. Sixty-three percent of patients presented a focal pattern, 22% a diffuse pattern, and 15% a combined one. Seventy-two percent of patients with lesions ≤ 10 mm presented stability, 27% a dimensional increase, and 1% a decrease. Patients with lesions >10 mm showed a statistically significant difference regarding the mean difference of axial diameter between T0 and Te (p = 0.015). Patients with lesions >10 mm showed an odds ratio (OR) of 29.8 (95%CIs 3.8-230.5) to develop at least one fracture. Mean TTF was significantly lower in patients with lesions >10 mm in comparison with lesions ≤ 10 mm (9 ± 3 vs 23 ± 7 months, respectively, p = 0.011). WBLDCT represents a reliable imaging-based tool for proper management of MM patients, showing that diffuse form or small lytic lesions may deserve a less frequent follow-up.

Keywords: Hematologic neoplasms; Multidetector computed tomography; Multiple myeloma; Osteolysis; Radiation dosage.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / diagnostic imaging*
  • Multiple Myeloma / pathology
  • Neoplasm Staging / methods
  • Radiation Dosage
  • Retrospective Studies
  • Tomography, X-Ray Computed / methods
  • Whole Body Imaging / methods